Infrequent opioid overdose risk reduction behaviours among young adult heroin users in cities with wide coverage of HIV prevention programmes

International Journal of Drug Policy

Volumn 22, Issue 1, 2011, Pages 16-25

  Neira León, Montserrat ^a   Barrio, Gregorio ^b,c   Bravo, María J ^b,c   Brugal, M Teresa ^b,d   de la Fuente, Luis ^b,c   Domingo Salvany, Antonia ^b,e   Pulido, José ^b,c   Santos, Sara ^b,c  

^a Secretaría Plan Nacional sobre el Sida   (Spain)

^b CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d AGÈNCIA DE SALUT PÚBLICA DE BARCELONA   (Spain)

^e HOSPITAL DEL MAR   (Spain)

Author keywords

Harm reduction programmes; Heroin injection; Overdose prevention

Indexed keywords

DIAMORPHINE; METHADONE; TRANQUILIZER;

ABSTINENCE; ADULT; ARTICLE; CITY; CONTROLLED STUDY; DRUG DEPENDENCE TREATMENT; DRUG INFORMATION; DRUG OVERDOSE; FEMALE; GEOGRAPHIC DISTRIBUTION; HEALTH BEHAVIOR; HEROIN DEPENDENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; POLICY; PREDICTION; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SPAIN;

ADULT; ANALGESICS, OPIOID; FEMALE; HEROIN; HEROIN DEPENDENCE; HIV INFECTIONS; HUMANS; MALE; OVERDOSE; QUESTIONNAIRES; RISK FACTORS; RISK REDUCTION BEHAVIOR; SPAIN; SUBSTANCE ABUSE, INTRAVENOUS; YOUNG ADULT;

EID: 79151477625     PISSN: 09553959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugpo.2010.06.003     Document Type: Article

References (59)

1. Agencia Antidroga de la Comunidad de Madrid Memoria 2001 [Annual Report 2001] 2002, Agencia Antidroga de la Comunidad de Madrid (AACM), Madrid.
2. Agencia Antidroga de la Comunidad de Madrid Memoria 2002 [Annual Report 2002] 2003, Agencia Antidroga de la Comunidad de Madrid (AACM), Madrid.
3. Agencia Antidroga de la Comunidad de Madrid Memoria 2003 [Annual Report 2003] 2004, Agencia Antidroga de la Comunidad de Madrid (AACM), Madrid.
4. Baca C.T., Grant K.J. Take-home naloxone to reduce heroin death. Addiction 2005, 100:1823-1831.
5. Bravo M.J., Barrio G., de la Fuente L., Royuela L., Domingo L., Silva T. Reasons for selecting an initial route of heroin administration and for subsequent transitions during a severe HIV epidemic. Addiction 2003, 98:749-760.
6. Bravo M.J., Royuela L., Barrio G., de la Fuente L., Suarez M., Brugal M.T. More free syringes, fewer drug injectors in the case of Spain. Social Science & Medicine 2007, 65:1773-1778.
7. Bravo M.J., Royuela L., de la Fuente L., Brugal M.T., Barrio G., Domingo-Salvany A., et al. Use of supervised injection facilities and injection risk behaviors among young drug injectors. Addiction 2009, 104:614-619.
8. Brugal M.T., Barrio G., de la Fuente L., Regidor E., Royuela L., Suelves J.M. Factors associated with non-fatal heroin overdose: Assessing the effect of frequency and route of heroin administration. Addiction 2002, 97:319-327.
9. Brugal M.T., Domingo-Salvany A., Puig R., Barrio G., Garcia de Olalla P., de la Fuente L. Evaluating the impact of methadone maintenance programmes on mortality due to overdose and aids in a cohort of heroin users in Spain. Addiction 2005, 100:981-989.
10. Darke S., Hall W. Heroin overdose: Research and evidence-based intervention. Journal of Urban Health 2003, 80:189-200.
11. Darke S., Zador D. Fatal heroin 'overdose': A review. Addiction 1996, 91:1765-1772.
12. Darke S., Ross J., Hall W. Overdose among heroin users in Sydney, Australia: I. Prevalence and correlates of non-fatal overdose. Addiction 1996, 91:405-411.
13. Darke S., Williamson A., Ross J., Mills K.L., Havard A., Teesson M. Patterns of nonfatal heroin overdose over a 3-year period: Findings from the Australian treatment outcome study. Journal of Urban Health 2007, 84:283-291.
14. Davoli M., Bargagli A.M., Perucci C.A., Schifano P., Belleudi V., Hickman M., et al. Risk of fatal overdose during and after specialist drug treatment: The VEdeTTE study, a national multi-site prospective cohort study. Addiction 2007, 102:1954-1959.
15. de la Fuente L., Bravo M.J., Lew C., Barrio G., Soriano V., Royuela L. Prevalencia de infección por el virus de la inmunodeficiencia humana y de conductas de riesgo entre los consumidores de heroína de Barcelona, Madrid y Sevilla: un ejemplo de las ventajas de centrar los estudios en los consumidores y no sólo en los usuarios por vía intravenosa [The prevalence of human immunodeficiency virus infection and the risk behaviors in the heroin addicts of Barcelona Madrid and Seville: An example of the advantages of centering studies on addicts and not just on intravenous users]. Medicina Clinica 1999, 113:646-651.
16. de la Fuente L., Brugal M.T., Ballesta R., Bravo M.J., Barrio G., Domingo-Salvany A., et al. Metodología del estudio de cohortes del Proyecto Itinere sobre consumidores de heroína en tres ciudades españolas y características básicas de los participantes [Cohort study methodology of the Itinere Project on heroin users in three Spanish cities and main characteristics of the participants]. Revista Española de Salud Pública 2005, 79:475-491.
17. de la Fuente L., Bravo M.J., Toro C., Brugal M.T., Barrio G., Soriano V., et al. Injecting and HIV prevalence among young heroin users in three Spanish cities and their association with the delayed implementation of harm reduction programmes. Journal of Epidemiology and Community Health 2006, 60:537-542.
18. de la Fuente L., Brugal M.T., Domingo-Salvany A., Bravo M.J., Neira-León M., Barrio G. Más de treinta años de drogas ilegales en España: una amarga historia con algunos consejos para el futuro. Revista Española de Salud Pública 2006, 80:505-520.
19. Des Jarlais D.C., Paone D., Milliken J., Turner C.F., Miller H., Gribble J., et al. Audio-computer interviewing to measure risk behaviour for HIV among injecting drug users: A quasi-randomised trial. The Lancet 1999, 353:1657-1661.
20. Delegación del Gobierno para el Plan Nacional sobre Drogas Estrategia Nacional sobre Drogas. Plan de Acción 2005-2008 [National strategy on drugs. Action plan 2005-2008] 2005, Delegación del Gobierno para el Plan Nacional sobre Drogas (DGPNSD). Ministrerio de Sanidad y Consumo, Madrid.
21. Delegación del Gobierno para el Plan Nacional sobre Drogas Memoria 2004 [Annual Report 2004] 2006, Delegación del Gobierno para el Plan Nacional sobre Drogas (DGPNSD). Ministerio de Sanidad y Consumo, Madrid.
22. Delegación del Gobierno para el Plan Nacional sobre Drogas Observatorio Español sobre Drogas (OED). Informe 2005-2006 2008, Delegación del Gobierno para el Plan Nacional sobre Drogas (DGPNSD). Ministerio de Sanidad y Consumo, Madrid.
23. Dietze P., Jolley D., Fry C.L., Bammer G., Moore D. When is a little knowledge dangerous? Circumstances of recent heroin overdose and links to knowledge of overdose risk factors. Drug and Alcohol Dependence 2006, 84:223-230.
24. Doe-Simkins M., Walley A.Y., Epstein A., Moyer P. Saved by the nose: Bystander-administered intranasal naloxone hydrochloride for opioid overdose. American Journal of Public Health 2009, 99:788-791.
25. European Monitoring Center for Drugs and Drug Addiction The state of the drugs problem in Europe. Annual Report 2008 2008, European Monitoring Center for Drugs and Drug Addiction (EMCDDA), Luxembourg.
26. European Monitoring Center for Drugs and Drug Addiction The state of the drugs problem in Europe. Annual Report 2009 2009, European Monitoring Center for Drugs and Drug Addiction (EMCDDA), Luxembourg.
27. Espelt A., Queralt A., Graugés D., García V., Vecino C., Brugal M.T. Actualització dels Indicadors de Drogues. 4 Trimestre 2008 [Update of Drug Indicators. 4th Quarter 2008] 2009, Agència de Salud Pública, Barcelona.
28. Evans J.L., Hahn J.A., Page-Shafer K., Lum P.J., Stein E.S., Davidson P.J., Moss A.R. Gender differences in Sexual and Injection Risk Behavior Among Active Young Injection Drug Users in San Francisco (the UFO study). Journal of Urban Health 2003, 80:137-146.
29. Farrell M., Marsden J. Acute risk of drug-related death among newly released prisoners in England and Wales. Addiction 2008, 103:251-255.
30. Galea S., Worthington N., Piper T.M., Nandi V.V., Curtis M., Rosenthal D.M. Provision of naloxone to injection drug users as an overdose prevention strategy: Early evidence from a pilot study in New York City. Addictive Behaviors 2005, 31:907-912.
31. Gonzalez-Saiz F., Lozano O.M., Ballesta R., Silva T., Brugal M.T., Bilbao I., et al. Validity of the Severity of Dependence Scale (SDS) construct applying the item response theory to a non-clinical sample of heroin users. Substance Use & Misuse 2008, 43:919-935.
32. Gossop M., Darke S., Griffiths P., Hando J., Powis B., Hall W., et al. The severity of dependence scale (SDS): Psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction 1995, 90:607-614.
33. Gossop M., Griffiths P., Powis B., Williamson S., Strang J. Frequency of non-fatal heroin overdose: Survey of heroin users recruited in non-clinical settings. British Medical Journal 1996, 313:402.
34. Green T.C., Grau L.E., Blinnikova K.N., Torban M., Krupitsky E., Ilyuk R., et al. Social and structural aspects of the overdose risk environment in St. Petersburg, Russia. International Journal of Drug Policy 2009, 20:270-276.
35. Heckathorn D.D. Respondent-driven sampling: A new approach to the study of hidden populations. Social Problems 1997, 44:174-179.
36. Hedrich D. European report on drug consumption rooms 2004, European Monitoring Centre for Drugs and Drug Addiction, Lisbon.
37. Ilundain E. Drogas, enfermedad y exclusión ¿Can Tunis (Barcelona) como paradigma? [Drugs, illness and exclusion ¿Can Tunis (Barcelona) as paradigm?] 2009, Fundación Medicina y Humanidades Médicas, Barcelona.
38. Langendam M.W., van Brussel G.H., Coutinho R.A., van Ameijden E.J. The impact of harm-reduction-based methadone treatment on mortality among heroin users. American Journal of Public Health 2001, 91:774-780.
39. McGregor C., Darke S., Ali R., Christie P. Experience of non-fatal overdose among heroin users in Adelaide, Australia: Circumstances and risk perceptions. Addiction 1998, 93:701-711.
40. Ministerial Council on Drug Strategy National heroin overdose strategy 2001, Commonwealth of Australia, Camberra.
41. Moore D. Governing street-based injecting drug users: A critique of heroin overdose prevention in Australia. Social Science & Medicine 2004, 59:1547-1557.
42. Morgan O., Vicente J., Griffiths P., Hickman M. Trends in overdose deaths from drug misuse in Europe: What do the data tell us?. Addiction 2008, 103:699-700.
43. MSIC Evaluation Committee Final report on the evaluation of the Sydney medically supervised injecting centre 2003, Authors, Sydney.
44. Neira-León M., Barrio G., Brugal M.T., de la Fuente L., Ballesta R., Bravo M.J., et al. Do young heroin users in Madrid, Barcelona and Seville have sufficient knowledge of the risk factors for unintentional opioid overdose?. Journal of Urban Health 2006, 83:477-496.
45. Newman J.C., Des Jarlais D.C., Turner C.F., Gribble J., Cooley P., Paone D. The differential effects of face-to-face and computer interview modes. American Journal of Public Health 2002, 92:294-297.
46. Piper T.M., Stancliff S., Rudenstine S., Sherman S., Nandi V., Clear A., et al. Evaluation of a naloxone distribution and administration program in New York City. Substance Use & Misuse 2008, 43:858-870.
47. Powis B., Strang J., Griffiths P., Taylor C., Williamson S., Fountain J., et al. Self-reported overdose among injecting drug users in London: Extent and nature of the problem. Addiction 1999, 94:471-478.
48. Rhodes T. Risk environments and drug harms: A social science for harm reduction approach. International Journal of Drug Policy 2009, 20:193-201.
49. Ruttenber A.J., Kalter H.D., Santinga P. The role of ethanol abuse in the etiology of heroin-related death. Journal of Forensic Sciences 1990, 35:891-900.
50. Seal K.H., Thawley R., Gee L., Bamberger J., Kral A.H., Ciccarone D., et al. Naloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent heroin overdose death: A pilot intervention study. Journal of Urban Health 2005, 82:303-311.
51. Secretaria del Plan Nacional sobre Sida ICAP Informe del cuestionario de actividades de prevención del VIH en las Comunidades Autónomas [ICAP. Report from the HIV prevention activities questionnaire in the Authonomous Communities] 2009, Retrieved 3 October 2009 from http://www.msc.es/gl/ciudadanos/enfLesiones/enfTransmisibles/sida/docs/ICAP2007/ICAP2007.pdf.
52. Sporer K.A. Acute heroin overdose. Annals of Internal Medicine 1999, 130:584-590.
53. Sporer K.A. Strategies for preventing heroin overdose. British Medical Journal 2003, 326:442-444.
54. Tobin K.E., Davey M.A., Latkin C.A. Calling emergency medical services during drug overdose: An examination of individual, social and setting correlates. Addiction 2005, 100:397-404.
55. Tobin K.E., Sherman S.G., Beilenson P., Welsh C., Latkin C.A. Evaluation of the Staying Alive programme: Training injection drug users to properly administer naloxone and save lives. International Journal of Drug Policy 2009, 20:131-136.
56. Trujols J. Take home naloxone: Life-saving intervention, medico-legal concern and heroin users' competence. British Medical Journal 2001, 322:895-896.
57. Vallejo F., Toro C., de la Fuente L., Brugal M.T., Barrio G., Soriano V., et al. Hepatitis B vaccination: An unmet challenge in the era of harm reduction programs. Journal of Substance Abuse Treatment 2007, 34:398-406.
58. van Ameijden E.J., Langendam M.W., Coutinho R.A. Dose-effect relationship between overdose mortality and prescribed methadone dosage in low-threshold maintenance programs. Addictive Behaviors 1999, 24:559-563.
59. Vicente J., Giraudon I., Matías J., Hedrich D., Wiessing L. Rebound of overdose mortality in the European Union 2003-2005: Findings from the 2008 EMCDDA Annual Report. Eurosurveillance 2009, 14.